Combination of peroxisome proliferator-activated receptor α/γ agonists may benefit type 2 diabetes patients with coronary artery disease through inhibition of inflammatory cytokine secretion

Author:        

Publisher: Spandidos Publications

ISSN: 1792-0981

Source: Experimental and Therapeutic Medicine, Vol.5, Iss.3, 2013-01, pp. : 783-788

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content